| pubmed-article:11249601 | pubmed:abstractText | BP-294 (a prodrug of R-alpha-methylhistamine) is a histamine H3 agonist under development by Bioprojet and in phase II clinical trials as an antiasthmatic [219798]. In a study, R-alpha-methylhistamine was shown to inhibit the release of acetylcholine, in the presence of atropine (1 microM) and 0.5 Hz of electrical stimulation of the rat bilateral vagus nerve, in a dose-dependent manner. This inhibition was abolished by thioperamide [321838]. | lld:pubmed |
